REYKJAVIK, Iceland, October 28 /PRNewswire-FirstCall/ -- deCODE genetics, Inc. (Nasdaq:DCGN) today announced that it will report its third quarter 2008 financial results in a press release to be issued on Thursday, November 6, after the close of the market in New York. The company will host a live webcast of its conference call to discuss these results and recent operating highlights on Friday, November 7, at 8am EST/1pm GMT.
The webcast can be accessed through the Investors page of deCODE's website, http://www.decode.com, or through http://www.earnings.com. Please log in to the webcast 15 minutes prior to the scheduled start of the call. The call will be archived for at least a week on each site. For those unable to listen to the webcast because of company firewall or other issues, a digitized audio replay will also be available by telephone from approximately 11:30am ET on Friday, November 7 and for one week thereafter. The dial-in replay numbers are: 1-(800)-475-6701 in the U.S., and +1-320-365-3844 for those calling from outside the U.S. The access code is 967723.
Any statements contained in this presentation that relate to future
plans, events or performance are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results, and the timing of events, to
differ materially from those described in the forward-looking statements.
These risks and uncertainties include, among others, those relating to our
ability to obtain financing and to form collaborative relationships, the
effect of a potential delisting of our common stock from The Nasdaq Global
Market, uncertainty regarding potential future deterioration in the market
for auction rate securities which could negatively affect our cash position
and result in additional permanent impairment charges, our ability to
develop and market diagnostic products, the level of third party
reimbursement for our products, risks related to preclinical and clinical
development of pharmaceutical products, including the identification of
compounds and the completion of clinical trials, the effect of government
regulation and the regulatory approval processes, market acceptance, our
ability to obtain and protect intellectual property rights for our
products, dependence on collaborative relationships, the effect of
competitive products, industry trends and other risks identified in
deCODE's filings with the Securities and Exchange Commission, including,
without limitation, the risk factors identified in our most recent Annual
Report on Form 10-K and any updates to those risk factors filed from time
to time in our Quarterly Reports on Form 10-Q or Current Reports on Form
8-K. deCODE undertakes no obligation to update or alter these
forward-looking statements as a result of new information, future events or
|SOURCE deCODE genetics Inc|
Copyright©2008 PR Newswire.
All rights reserved